Trial reportAmerican heart journal2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.
Trial report in American heart journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 231 citations in OpenAlex.
- Pediatric Heart Network Trial of Losartan vs. Atenolol in Children and Young Adults with Marfan Syndrome: Impact on Prescription Practices.Pediatric cardiology · 2023Trial
- Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.The Journal of pediatrics · 2020Trial
- Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.The Journal of pediatrics · 2019Trial
- Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome.Pediatric cardiology · 2018Trial
- Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.The American journal of cardiology · 2018Trial
- Atenolol versus losartan in children and young adults with Marfan's syndrome.The New England journal of medicine · 2014Trial
- Trial
- Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.American heart journal · 2013Trial
- Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study.American heart journal · 2011Trial
- Angiotensin II blockade and aortic-root dilation in Marfan's syndrome.The New England journal of medicine · 2008Trial
- Prevalence and management of hypertension in Turner syndrome: data from the International Turner Syndrome (I-TS) registry.Endocrine connections · 2025Article
- Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- Role of Clinical Genetic Testing in the Management of Aortopathies.Current cardiology reports · 2021Review
- Loeys-Dietz Syndrome.Advances in experimental medicine and biology · 2021Article
- Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience.Clinical trials (London, England) · 2020Article
- Pharmacogenetic factors affecting β-blocker metabolism and response.Expert opinion on drug metabolism & toxicology · 2020Review
- A scoping review presenting a wide variety of research on paediatric and adolescent patients with Marfan syndrome.Acta paediatrica (Oslo, Norway : 1992) · 2020Article
- Anatomically specific reactive oxygen species production participates in Marfan syndrome aneurysm formation.Journal of cellular and molecular medicine · 2019Article
- Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.The American journal of cardiology · 2018Article
- TGF-β Family Signaling in Connective Tissue and Skeletal Diseases.Cold Spring Harbor perspectives in biology · 2017Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 13 institutions in 2 countries.
Funding
Abstract
backgroundCardiovascular disease, including aortic root dilation, dissection, and rupture, is the leading cause of mortality in patients with Marfan syndrome (MFS). The maximal aortic root diameter at the sinuses of Valsalva is considered the best predictor of adverse cardiovascular outcome. Although advances in therapy have improved life expectancy, affected individuals continue to suffer cardiovascular morbidity and mortality. Recent studies in an FBN1-targeted mouse model of MFS with aortic disease similar to that seen in humans showed that treatment with losartan normalized aortic root growth and aortic wall architecture.
methodsThe Pediatric Heart Network designed a randomized clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in subjects with MFS receiving atenolol or losartan. Individuals 6 months to 25 years of age with a body surface area-adjusted aortic root z score >3.0 will be eligible for inclusion. The primary aim is to compare the effect of atenolol therapy with that of losartan therapy on the rate of aortic root growth over 3 years. Secondary end points include progression of aortic regurgitation; incidence of aortic dissection, aortic root surgery, and death; progression of mitral regurgitation; left ventricular size and function; echocardiographically derived measures of central aortic stiffness; skeletal and somatic growth; and incidence of adverse drug reactions.
conclusionThis randomized trial should make a substantial contribution to the management of individuals with MFS and expand our understanding of the mechanisms responsible for the aortic manifestations of this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.